glp-1 news november 2025 Eli Lilly to seek approval of new weight-loss drug this year GLP-1 Pipeline Update: November 2025

Secondary outcomes included nonfatal MI, nonfatal stroke, HHF and renal composite outcome, defined in most trials as a composite of progression to end-stage renal disease or a sustained decrease of at least 40% in estimated glomerular filtration rate (eGFR)

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

Liraglutide effects on brain glucose metabolism in Alzheimers disease: A randomized controlled trial

Check the packaging for proper branding, lot numbers, expiration dates, and security features

So those indirect winds we are starting to look at like, wow, there's some benefit to your brain as well